Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.
In early February, global biopharmaceutical company Sanofi and biotechnology company Regeneron Pharmaceuticals, Inc. ("Regeneron") shared that its dually developed drug Libtayo (cemiplimab-rwlc) recently received FDA approval. Now, Libtayo stands as…
Recently, biopharmaceutical company GenSight Biologics ("GenSight") announced the publication of data from a study evaluating GS030-Drug Products (GS030-DP or "GS030") as a potential treatment option for retinitis pigmentosa (RP). Although…
There are many forms of birth control available: oral contraceptives (birth control pills), intrauterine devices (IUDs), the implant or patch, condoms. But according to Cancer Therapy Advisor, a new study…
In early February, pharmaceutical company Ellodi Pharmaceuticals ("Ellodi") shared that its drug candidate, APT-1011, received the FDA's Fast Track designation. APT-1011, or fluticasone propionate oral disintegrating tablet, is designed to…
424 words (source) vs. 431 words (mine) - 3% match Earlier this week, Guinea, a country located in West Africa, reported new cases of Ebola, a rare and deadly infection.…
Clinical stage pharmaceutical company KalVista Pharmaceuticals ("KalVista") saw positive data from a Phase 2 clinical trial evaluating its experimental therapy KVD900, shared MedCity News. The Phase 2 trial was exploring…
The first patient has been dosed in a Phase 1 clinical trial, which is exploring Curis Inc.'s CA-4948 in conjunction with ibrutinib for hematologic malignancies. Examples of hematologic malignancies include…
According to Charcot-Marie-Tooth News, researchers have discovered a new subtype of Charcot-Marie-Tooth disease (CMT) linked to the sorbitol dehydrogenase (SORD) gene. Read the full study findings published in Nature Genetics. SORD Gene…
Researchers have not always understood why some people develop Addison's disease, a rare autoimmune condition affecting the adrenal glands, over others. Now, a new study conducted by Swedish and Norwegian…
In the past, patients with short bowel syndrome (SBS) were treated with teduglutide, a daily injection. However, injections can be painful, difficult to administer, and unfortunately not as targeted.…
Developed by United Therapeutics Corporation ("United") and DEKA Research and Development Corporation ("DEKA"), the Remunity Pump is now commercially available for patients with pulmonary arterial hypertension (PAH). On February…
In a recent press release, pharmaceutical company Moleculin Biotech, Inc. ("Moleculin") shared a recent advance in the sphere of medical and health research. Agencja Badań Medycznych, a Polish agency which contributes…
During clinical trials, researchers work to advance clinical knowledge, build an understanding of certain diseases or conditions, and learn more about a new drug, surgical device, or behavioral modification technology. However,…
According to ForexTV, commercial gene therapy company Spark Therapeutics ("Spark") recently announced preliminary data from a Phase 1/2 clinical trial evaluating SPK-8016, an investigational gene therapy, for patients with hemophilia…
The American Society of Clinical Oncology will soon hold their Genitourinary Cancers Symposium (ASCO GU) from February 11 through 13, 2021. The symposium, held virtually during COVID-19, will feature…
In early February, global healthcare company Insightec shared that the company received FDA approval for its new study. Within the study, Insightec will evaluate Focused Ultrasound as a potential…
After in-licensing Icatibant, a Bradykinin B2 receptor agonist, from Slayback Pharma, global pharmaceutical and biosimilar leader Sandoz is launching a generic version in the United States. According to a…
According to Oncology Nursing News, a new study performed by researchers at the Baylor College of Medicine used germline testing to identify genetic precursors to pediatric rhabdomyosarcoma. The study identified…
In a recent press release, biopharmaceutical company AstraZeneca announced that its drug CALQUENCE (acalabrutinib) met both its primary and secondary endpoints in the Phase 3 ELEVATE-RR clinical trial. These endpoints…
On February 8, 2021, global biopharmaceutical company Bristol Myers Squibb shared that the European Commission (EC) approved a Marketing Authorization Application (MAA) for Inrebic (fedratinib). For around 10 years, there…
Since its inception, biopharmaceutical company Reistone Biopharma Co. Ltd. ("Reistone") has worked to develop treatment options for patients with immuno-inflammatory and autoimmune conditions. Most recently, their drug candidate SHR0302,…
In an early February press release, pharmaceutical company Astellas Pharma Inc. ("Astellas") shared that XOSPATA (gilteritinib) was given conditional approval in China for the treatment of patients with FLT3-mutated…
On her 23rd birthday, Sara Lefebvre almost died. After having some drinks with friends, her friend drove Sara home. But Sara didn't make it inside; she collapsed in sub-zero temperatures,…
According to Medical XPress, new research suggests that removing microRNA from triple negative breast cancer cells can reduce the cancer's spread and progression. The research also found that microRNA could…
In a recent press release, biopharmaceutical company Junshi Biosciences ("Junshi") announced a burgeoning collaboration with leading biologics platform company Coherus BioSciences, Inc. ("Coherus"). The pair is working to develop and…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
